Tanvex BioPharma, Inc. (TPE:6541)

Market Cap	12.04B
Revenue (ttm)	81.18M
Net Income (ttm)	-1.43B
Shares Out	238.49M
EPS (ttm)	-8.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	127,632
Average Volume	284,415
Open	50.50
Previous Close	50.50
Day's Range	49.50 - 50.60
52-Week Range	39.25 - 82.00
Beta	-0.04
RSI	33.51
Earnings Date	Aug 8, 2025

About Tanvex BioPharma

Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company’s products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. T...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 198
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6541

Financial Performance

In 2024, Tanvex BioPharma's revenue was 34.68 million, a decrease of -43.53% compared to the previous year's 61.41 million. Losses were -1.38 billion, -35.35% less than in 2023.